EA202192288A1 - Соединения на основе нейрегулина-4 и способы их применения - Google Patents

Соединения на основе нейрегулина-4 и способы их применения

Info

Publication number
EA202192288A1
EA202192288A1 EA202192288A EA202192288A EA202192288A1 EA 202192288 A1 EA202192288 A1 EA 202192288A1 EA 202192288 A EA202192288 A EA 202192288A EA 202192288 A EA202192288 A EA 202192288A EA 202192288 A1 EA202192288 A1 EA 202192288A1
Authority
EA
Eurasian Patent Office
Prior art keywords
neuregulin
methods
application
compounds based
compounds
Prior art date
Application number
EA202192288A
Other languages
English (en)
Inventor
Джонатан Уэсли Дей
Йосеф Джордж Хойер
Авинаш Муппиди
Уэй Ни
Джеймс Дэвид Панкук
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202192288A1 publication Critical patent/EA202192288A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к соединениям на основе нейрегулина (NRG) 4 и к способам лечения соединениями NRG4.
EA202192288A 2019-04-01 2020-03-31 Соединения на основе нейрегулина-4 и способы их применения EA202192288A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827386P 2019-04-01 2019-04-01
PCT/US2020/025921 WO2020205840A1 (en) 2019-04-01 2020-03-31 Neuregulin-4 compounds and methods of use

Publications (1)

Publication Number Publication Date
EA202192288A1 true EA202192288A1 (ru) 2022-01-21

Family

ID=70465394

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192288A EA202192288A1 (ru) 2019-04-01 2020-03-31 Соединения на основе нейрегулина-4 и способы их применения

Country Status (23)

Country Link
US (2) US11242370B2 (ru)
EP (1) EP3947428A1 (ru)
JP (1) JP7036953B2 (ru)
KR (1) KR20210134699A (ru)
CN (1) CN113677699A (ru)
AR (1) AR121035A1 (ru)
AU (1) AU2020252184B2 (ru)
BR (1) BR112021017670A2 (ru)
CA (2) CA3132135A1 (ru)
CL (1) CL2021002455A1 (ru)
CO (1) CO2021012807A2 (ru)
CR (1) CR20210474A (ru)
DO (1) DOP2021000194A (ru)
EA (1) EA202192288A1 (ru)
EC (1) ECSP21072840A (ru)
IL (1) IL286697A (ru)
JO (1) JOP20210264A1 (ru)
MA (1) MA55532A (ru)
MX (1) MX2021011983A (ru)
PE (1) PE20212326A1 (ru)
SG (1) SG11202110484VA (ru)
TW (1) TWI787596B (ru)
WO (1) WO2020205840A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023150693A2 (en) * 2022-02-03 2023-08-10 Avexegen Therapeutics, Inc. Neuregulin-4 analogs and methods of using thereof in disease treatment
WO2023230491A1 (en) 2022-05-25 2023-11-30 Eli Lilly And Company Methods of using neuregulin-4 compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
JP2003510029A (ja) 1999-08-20 2003-03-18 カイロン コーポレイション Ｅｇｆｈ２遺伝子および遺伝子産物
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
CA2808215A1 (en) 2000-05-23 2001-11-29 Cenes Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2003014159A1 (en) 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
US20090131308A1 (en) 2003-08-19 2009-05-21 Agos Biotech Ltd. Splice Variants of ErbB Ligands, Compositions and Uses Thereof
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
JP2009539412A (ja) 2006-06-12 2009-11-19 レセプター バイオロジックス， インコーポレイテッド 汎細胞表面レセプター特異的な治療薬
ES2315110B1 (es) 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
CN101310779A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN101397337A (zh) * 2007-09-25 2009-04-01 上海泽生科技开发有限公司 神经调节蛋白突变体及其用途
BRPI0916442A2 (pt) 2008-07-17 2018-06-19 Acorda Therapeutics, Inc. dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca
EP3173091B1 (en) 2008-08-15 2020-07-22 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
CN102232084B (zh) 2008-11-28 2014-05-28 上海泽生科技开发有限公司 纽兰格林及其用途
CN102231987A (zh) 2008-11-28 2011-11-02 上海泽生科技开发有限公司 纽兰格林和心脏干细胞
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
EP2493495A4 (en) 2009-07-10 2013-08-21 Univ Northwestern HERZSCHÜTZENDE ROLE OF LIVER CELLS AND SEKRETORIC FACTORS FROM LIVER CELLS IN MYOCARDIAN EMERGENCE
WO2011011388A2 (en) 2009-07-22 2011-01-27 Children's Medical Center Corporation Neuregulin induced regeneraton of heart muscle muscle
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
EP2744512B1 (en) 2011-08-15 2019-07-03 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US8748131B2 (en) 2012-09-26 2014-06-10 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
WO2014051567A1 (en) 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2904055A1 (en) 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
US9878010B2 (en) 2013-03-21 2018-01-30 The Regents Of The University Of Michigan Methods of treating metabolic disorders
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN104211799B (zh) 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
US9352923B2 (en) 2014-02-26 2016-05-31 Eastman Kodak Company Air shoe with roller providing lateral constraint
WO2015158743A1 (en) 2014-04-15 2015-10-22 Universiteit Antwerpen Treatment of nephropathy
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3247380A1 (en) 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US10017574B2 (en) 2015-05-07 2018-07-10 Yeda Research And Development Co. Ltd. Methods, kits and devices for promoting cardiac regeneration
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
CN113166218A (zh) 2018-04-11 2021-07-23 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso

Also Published As

Publication number Publication date
TWI787596B (zh) 2022-12-21
CL2021002455A1 (es) 2022-05-27
ECSP21072840A (es) 2021-11-18
PE20212326A1 (es) 2021-12-14
CN113677699A (zh) 2021-11-19
CR20210474A (es) 2021-10-13
BR112021017670A2 (pt) 2021-11-16
TW202104251A (zh) 2021-02-01
MX2021011983A (es) 2021-11-03
KR20210134699A (ko) 2021-11-10
DOP2021000194A (es) 2021-10-31
US20220112255A1 (en) 2022-04-14
CA3132135A1 (en) 2020-10-08
AU2020252184B2 (en) 2022-12-08
JP2021522314A (ja) 2021-08-30
CA3223554A1 (en) 2020-10-08
AR121035A1 (es) 2022-04-13
US11242370B2 (en) 2022-02-08
US20200354421A1 (en) 2020-11-12
MA55532A (fr) 2022-02-09
EP3947428A1 (en) 2022-02-09
WO2020205840A1 (en) 2020-10-08
IL286697A (en) 2021-10-31
AU2020252184A1 (en) 2021-10-14
JOP20210264A1 (ar) 2023-01-30
JP7036953B2 (ja) 2022-03-15
CO2021012807A2 (es) 2021-10-29
SG11202110484VA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA202191519A1 (ru) Модуляторы trex1
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA202092692A1 (ru) Аналоги рапамицина и их применения
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202092748A1 (ru) Модуляторы экспрессии apol1
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
EA202190888A1 (ru) Пептид для применения в косметике
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
PH12021550122A1 (en) Solubilized apyrases, methods and use
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
UY38472A (es) Moduladores de la expresión de foxp3
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EA202192101A1 (ru) Соединения и их применение
EA201992532A1 (ru) Композиции и способ для лечения депрессии
EA202091742A1 (ru) ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck